Back to search

Article

Cost-effectiveness of PARP inhibitors for maintenance therapy of patients with a BRCA mutation and primary epithelial ovarian cancer in China

2024-04-30

Abstract excerpt

<title>Abstract</title> <p>Background Maintenance therapy with poly (ADP-ribose) polymerase inhibitors (PARPis) plays a crucial role in managing primary epithelial ovarian cancer (OC), especially in patients with a BRCA mutation. However, there is a lack of economic evaluation comparing various PARPis. Aim This study aimed to investigate the cost-effectiveness of fuzuloparib compared to routine surveillance, ol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ecf3790b-56c7-5f90-84b7-8e8d66644b08
DOI
10.21203/rs.3.rs-4215728/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cost-effectiveness of PARP inhibitors for maintenance therapy of patients with a BRCA mutation and primary epithelial ovarian cancer in ChinaDOI 10.21203/rs.3.rs-4215728/v1
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.Semantic proximity
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerSemantic proximity
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.Semantic proximity
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.Semantic proximity
Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.Semantic proximity
Efficacy and safety analysis of PARP inhibitors combined with drugs for primary and relapsed ovarian cancer: A meta-analysis of randomized controlled trialsSemantic proximity
Cost-Effectiveness Analysis of talazoparib Maintenance Treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the USSemantic proximity
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy.Semantic proximity
Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.Semantic proximity
Health-Related Quality of Life in PARP-Inhibitor Olaparib Maintenance in Ovarian Cancer Patients: Real World Data and Experience of a Single-Center in ChinaSemantic proximity
Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials.Semantic proximity
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.Semantic proximity
Select a neighboring publication to make it the new centre.